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Abstract
Background: Nowadays, more breast cancer patients want to have children after the diagnosis of
cancer. The purpose of this study is to review the possibility and risks of giving birth among women
with breast cancer previously treated by chemotherapy.
Case presentation: Two young women aged 28 and 34 respectively, were treated in our clinic
for breast cancer, the first (negative hormonal receptors) by surgery, chemotherapy and
radiotherapy and the second (positive hormonal receptors) by surgery, radiotherapy and
tamoxifen. They both became pregnant, 1 and 8 years after completion of the therapy respectively.
Results: Laboratory testing during pregnancy was negative in both cases and after an uneventful
course each woman gave birth to a perfectly healthy child. The first patient breastfed her baby for
three months, while the second one did not breastfeed her baby at all.
Conclusion: Women undergoing chemotherapy for breast cancer can maintain their fertility and
get pregnant. Previous chemotherapy for breast cancer does not present any supplementary risks
for the child's mental or physical health.
Introduction
Women, nowadays, delay their childbirth to the 30ies.
Therefore, more breast cancer patients have not com-
pleted their family planning and desire to have children
after the diagnosis of breast cancer, though, there are no
valid treatment options for preserving ovarian function
after chemotherapy. Many authors believe that there is no
increased risk for relapse if a breast cancer patient
becomes pregnant. However, the timing of pregnancy has
not yet been fixed. It depends on the factors of prognosis,
the age, the personal situation and personal preferences
[1].
Case presentation 1
A twenty-eight year old female patient presented to the
breast clinic with a palpable painful mass on the upper
lateral quadrant of the right breast, measuring 3 × 4 cm2.
Upon further questioning, menarche occurred at the age
of thirteen and it was stated that her menstrual cycle was
regular. The patient denied use of contraceptive pills. No
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birth, miscarriage or abortion is mentioned. The patient
was a smoker. There were no inherited diseases or family
history of cancer.
A biopsy under general anesthesia was performed, which
was positive; therefore an extended tumorectomy and rad-
ical lymph node dissection were performed. The histolog-
ical testing showed invasive ductal carcinoma of myeloid
type, grade III with 4/12 of the axillary lymph glands
involved, as well as coexistence of carcinomatic emboli to
the lymphatic vessels. The surgical margins were clear of
neoplasmatic cells. The tumor was negative to PR and ER:
5% progesterone receptors, 10% estrogen receptors, 0%
p53, c-erbB-2: score +3, 60%, ki 67. The patient received
chemotherapy (clitaxel, epirubicin, paclitaxel, cyclophos-
phamide, methotrexate) for four months and radiother-
apy for one month.
A year after the accomplishment of the adjuvant treat-
ments she got pregnant and was under supervision there-
after. The pregnancy was uneventful and a healthy child
with no health problems (normal physical and mental
development) was born, by natural labor.
The patient breastfed her baby for three months. Routine
follow-ups were performed every month, included ultra
sound (U/S) cancer ratings, with normal findings.
Four years post-labor, the patient remains free of disease.
Case presentation 2
A thirty-four-year old female patient presented to the
breast clinic with a palpable painless mass on the upper
lateral quadrant of the right breast. Menarche occurred at
the age of fourteen, as well as regular menstrual cycle was
stated. No contraceptive pills use is mentioned. It was also
mentioned that she has had children, no miscarriage or
abortion. The patient was a smoker. Her family medical
record was also free of inherited diseases or cancer.
The patient was submitted to immediate biopsy under
general anesthesia (which was positive). Therefore, a
broad resection of the quadrant of the right breast with
respective lymphadenic care was performed. The histolog-
ical testing showed ductal invasive carcinoma grade II
with 2/13 of the axillary lymph glands involved. The sur-
gical limits were clear of neoplasmatic cells. The tumor
was positive to ER and PR: 90% progesterone receptors,
80% estrogen, 0% p53, c-erbB-2: score+1, 15% ki 67. The
patient received radiotherapy for two months (40 ses-
sions) and she was given anti-estrogen (Tamoxifen) for
two and a half years, which was discontinued due to the
occurrence of ovary cysts and menstrual disturbances.
Eight years after the accomplishment of the adjuvant treat-
ments she got pregnant under supervision. The pregnancy
was uneventful and a healthy child was born via a caesar-
ian incision. The patient did not breastfeed her baby. Rou-
tine follow-ups were performed every month, included
ultra sound (U/S) and cancer indexes testing, which both
proved to be negative throughout the whole period.
Thus, twelve years post-mastectomy, during the check-up
performed with bone CT scanning, deposits were found
on the bones and the ultra-sound showed liver metastasis,
measuring approximately 3 cm. The patient received
chemotherapy (Fluorouracil, Adriamycin, Cyclophospha-
mide) for six months. After the six-month period she con-
tinued Tbs treatment (Noveldin) for three months.
Till present, according to the C/T scans, the metastasis in
the liver measures 1 to 1,5 cm and the patient continues
her treatment with Zometan for bone deposits.
Generally patients were monthly checked by clinical eval-
uation, cancer indices rating (CEA, Ca 125, Ca 153) and
breast U/S during pregnancy and immediately after birth;
Thereafter, they should be checked every three-six-nine-
twelve months and then yearly with the addition of CT
scanning of thorax, CT of upper and lower abdomen and
bone scanning.
Discussion
Cancer is the leading cause of death among women, aged
25–55. Among the new cases of breast cancer diagnosed,
approximately 10% are women younger than 44 years of
age.
Young breast cancer survivors and their spouses may face
a difficult dilemma regarding their wish to have children.
As a result of new developments in breast cancer treat-
ment, more women are cured or remain in long-term
remission after being diagnosed with breast cancer. This,
along with the growing trend in western societies for
women to delay childbirth, results in an increasing
number of young breast cancer survivors, who have not
yet started or completed their childbearing years [2-4].
The common recommendation for women with early
stages of breast cancer is to wait at least 6 months up to
two years after the end of their treatment before trying to
become pregnant, because most of the recurrences of can-
cer occur during this period of time [5].
It has been shown that the majority of women, younger
than 35 years of age experience only temporary amenor-
rhea due to chemotherapy and can maintain fertility [6].
The medical literature has not demonstrated a survival
disadvantage [3,5-7], or a higher proportion of distantInternational Seminars in Surgical Oncology 2009, 6:7 http://www.issoonline.com/content/6/1/7
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metastasis [8], in women who have given birth after breast
cancer compared to women who have not given birth after
breast cancer. In addition, although chemotherapy has
been shown to result in increased miscarriage frequency
[7], children born to mothers who have received chemo-
therapy are not at a higher risk for congenital defects com-
pared to the general population [9]. Nevertheless, in their
latest review on the subject, Upponi SS et al [10] con-
cluded that "the effect of subsequent pregnancy on
patients who have had breast cancer with regard to local
recurrence, distant metastasis and survival remains debat-
able, due to sampling and methodological limitations
(eg, Retrospective studies)". There is concern with subse-
quent pregnancy after breast cancer treatment that a high
concentration of estrogen in the blood during pregnancy
may contribute to breast cancer recurrence [5,9]. In addi-
tion, it was found that pregnancy is a risk factor of devel-
opment of breast cancer among carriers of BRCA1 and
BRCA2 genetic mutations [11]. It has been assumed that
the immuno-suppressant and hormonal effects of preg-
nancy so close to diagnosis and during treatment may
have a significant deleterious effect. Consistent with this
theory, Nugent and O'Connell reported a worse outcome
for women with early subsequent pregnancy. Other
authors have refused this, showing no worse outcome
with subsequent pregnancy. In fact, women who have a
subsequent pregnancy have equivalent or, possibly, better
survival matched for stage. Although this suggests that
subsequent pregnancy may provide a survival benefit,
there may be observational bias involved, with only a
selected group of women, who feel healthy give birth and
those who are affected by the disease do not: a "healthy
mother" effect [12,13]. There are many aspects that need
to be considered when pregnancy (planned or not) is a
possibility subsequent to a diagnosis of breast cancer.
These include social, psychological, economic, and bio-
logical issues in a woman who has a potentially limited
lifespan. The woman (and her family) will have concerns
about whether she will remain fertile following treatment,
what influence a subsequent pregnancy may have on
recurrence of breast cancer and its consequences, and
whether the child may inherit a familial tendency towards
breast cancer [4].
Recently, at the ninth St Gallen expert consensus meeting
in January 2005, the experts suggested that women with
breast cancer should be offered chemotherapy for endo-
crine non-responsive disease and endocrine therapy as the
primary therapy for endocrine responsive disease, adding
chemotherapy for some intermediate- and all high risk
groups in this category [14]. Just as limited surgery, chem-
otherapy and endocrine therapy allows conservation of
the breast and unaffected lymph nodes and limited radia-
tion therapy is being studied, thus appropriate adjuvant
systemic therapy involves choosing treatments tailored to
individual patients according to assessment of endocrine
responsiveness [14]. Concerning the matter of metastases,
the hypothesis that a subset of tumor cells ('tumor stem
cells') are responsible for invasion and metastases, while
other tumor cells are not tumorigenic, is supported by
experiments on human breast cancer cells in immuno-
compromised mice [15,16]. A specific gene expression sig-
nature seems to characterize these cells and even
specifically be associated with an organ specific metastatic
potential [17].
Such stem cells might become a major target for tailored
therapies.
Prognosis of DCIS, which both of our patients presented,
is associated with size, grade, distance to resection mar-
gins, degree of ER expression and age. Tamoxifen reduces
recurrence of receptor positive DCIS, but shows little evi-
dence of benefit in receptor negative disease [18]. Radio-
therapy reduces in situ and invasive recurrence but is
sometimes omitted, especially for small low-grade lesions
[19,20], as the second patient was treated. Moreover, ster-
oid hormone receptors (Era, PgR), according to new data,
are overwhelmingly indicative of endocrine responsive-
ness, though not all tumors expressing detectable hor-
mone receptors will have a clinically useful response, like
in the case of the second patient. Tumors completely lack-
ing such receptors were found to be particularly sensitive
to preoperative cytotoxic agents, but despite a pathologi-
cal complete remission rate exceeding 30%, survival of
patients with this phenotype was shorter than for patients
with receptor-positive tumors who obtained pathological
complete remission significantly less frequently [21].
Exclusion of multifocal disease by MRI may improve
selection for conservative surgery.
The second patient was not submitted to MRI control, but
she presented an interval free of disease. Conservation of
the nipple-areola complex during mastectomy, with
immediate breast reconstruction, while well accepted by
patients [22], requires careful patient selection and
patient information on limited long-term experience.
Breast radiation reduces relapses in the breast and chest
wall. On the average, for patients at high risk of local
relapse, radiation therapy was also shown to improve sur-
vival [23]. Radiation therapy is clearly indicated after
breast conserving surgery including a boost in younger
patients. It remains uncertain whether radiation therapy
may be omitted for women above the age of 70 years with
clear margins who also receive adjuvant endocrine ther-
apy [24]. The aforementioned are proved through the
cases of our two patients.International Seminars in Surgical Oncology 2009, 6:7 http://www.issoonline.com/content/6/1/7
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The Columbia study was updated at a median of 20 years
and concluded that for patients with high-risk breast can-
cer radiation therapy and adjuvant chemotherapy yielded
better survival than chemotherapy alone [25]. This fact is
greatly proved in case one, where combined therapy was
applied, while in the second case it raised the negative
effects of its application.
For premenopausal women with endocrine responsive
disease, combined ovarian function suppression (gosere-
lin) and tamoxifen appeared to be as effective as CMF
chemotherapy [26,27]. The addition of tamoxifen after
chemotherapy reduced relapse in premenopausal women
with endocrine-responsive tumors but the same study
found a detrimental impact of tamoxifen on disease-free
survival in endocrine non-responsive disease [28]. Thus,
correctly the first woman was not given tamoxifen, while
no chemotherapy was given in the second case, which
proved to lead to bad results.
Very young patients have a worse prognosis compared to
older premenopausal women presenting with otherwise
similar cancer [29,30]. Three high priority trials are specif-
ically investigating ovarian function suppression (SOFT),
an aromatase inhibitor (TEXT) and the need for chemo-
therapy (PERCHE) in adjuvant therapy for endocrine
responsive breast cancer in young women [26,27].
Although p53 protein accumulation and gene mutation
were implicated in resistance to chemotherapy, the clini-
cal value of these findings remains controversial [31,32].
Similarly, multi-gene assay (eg, Oncotype DX for 16
genes) by RT-PCR was found to be useful for defining a
group of patients with estrogen receptor positive disease
who would benefit from chemotherapy added to
tamoxifen [33], but further prospective validation of this
method is required.
Treatment choice depends upon potential endocrine
responsiveness although most studies have used chemo-
therapy, frequently containing anthracyclines and tax-
anes. In a small randomized study (42 patients) neo-
adjuvant trastuzumab plus chemotherapy yielded a
higher pathologic complete response rate than chemo-
therapy alone for patients with HER2-positive disease
[34]. These data require confirmation.
Endocrine neoadjuvant therapy has also been successful
[35,36]. Remaining questions include chemotherapy
combined with endocrine treatments (eg, Aromatase
inhibitors) and duration of systemic therapy for best tim-
ing of surgery [21].
Conclusion
Healthy pregnancy can occur even after chemotherapy
with no consequences for the fetus or even later for the
child. These patients are of remarkable interest.
Even if there are various studies suggesting controversial
results, concerning the hormonal receptors and the asso-
ciated risk of tumorigenesis among young women, in
cases of hormone-dependent cancer, it seems that hormo-
nal receptors have the most important role regarding the
patients outcome [14].
In conclusion, the possibility of recurrence of the disease
remains a constant life long hazard, which seems to be
related to the specific characteristics of the tumor and
mainly, to hormonodependence.
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